Stay updated on CD19/CD22 CAR T Cells in Pediatric B Cell Malignancies Clinical Trial
Sign up to get notified when there's something new on the CD19/CD22 CAR T Cells in Pediatric B Cell Malignancies Clinical Trial page.

Latest updates to the CD19/CD22 CAR T Cells in Pediatric B Cell Malignancies Clinical Trial page
- CheckyesterdayChange DetectedThe study title and description were updated to reflect a new, more detailed Phase I/II CD19/CD22-CAR T cell trial in children and young adults with B cell malignancies. The update adds phase-specific design elements, dosing cohorts, and eligibility details, while older wording was removed or superseded to align with the new structure.SummaryDifference3%

- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe page shows Revision: v3.5.4, indicating a new release of the page template. This metadata update does not modify study details, eligibility criteria, or contact information.SummaryDifference0.0%

- Check23 days agoNo Change Detected
- Check37 days agoChange DetectedClinicalTrials.gov’s page footer now shows a newer software/revision version (v3.5.3 instead of v3.5.2) for the site build, without impacting the study content.SummaryDifference0.0%

- Check45 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check59 days agoChange DetectedAdded B-cell chronic lymphocytic leukemia to the study's listed conditions. This expands the potential disease scope for inclusion.SummaryDifference0.0%

- Check73 days agoChange DetectedRevision tag updated from v3.4.3 to v3.5.0 on the page. This update does not affect the study details, eligibility, or other user-facing content.SummaryDifference0.0%

Stay in the know with updates to CD19/CD22 CAR T Cells in Pediatric B Cell Malignancies Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CD19/CD22 CAR T Cells in Pediatric B Cell Malignancies Clinical Trial page.